No, perimesencephalic SAH does not require Keppra (levetiracetam)
Perimesencephalic SAH is a distinct, benign subtype of subarachnoid hemorrhage with an excellent prognosis and extremely low seizure risk—prophylactic antiseizure medications are not indicated.
Key Distinction: Perimesencephalic vs Aneurysmal SAH
Perimesencephalic SAH represents a fundamentally different entity from aneurysmal SAH (aSAH). The evidence and guidelines you're encountering address aneurysmal SAH, not perimesencephalic SAH. This distinction is critical:
- Perimesencephalic SAH: Non-aneurysmal, benign bleeding pattern centered around the midbrain, no vasospasm risk, no seizure risk, excellent outcomes
- Aneurysmal SAH: Ruptured aneurysm, high-grade bleeding, risk of vasospasm, delayed cerebral ischemia, and seizures
Evidence for Aneurysmal SAH (Not Applicable Here)
The 2023 AHA/ASA guidelines 1 specifically address aneurysmal SAH and recommend:
- No prophylactic ASM for low-risk aSAH (no MCA aneurysm, low-grade SAH, no ICH, no hydrocephalus, no cortical infarction)
- Consider prophylactic ASM only for high-risk features (ruptured MCA aneurysm, high-grade SAH, ICH, hydrocephalus, cortical infarction)
- Avoid phenytoin due to excess morbidity and mortality
- Short duration only (≤7 days) if seizures occur at presentation
The Neurocritical Care Society guidelines 2 similarly provide only conditional recommendations for aSAH, acknowledging low-quality evidence and suggesting ASM use is optional even in aneurysmal cases.
Why Perimesencephalic SAH is Different
Perimesencephalic SAH patients have:
- No aneurysm (negative angiography)
- No high-risk features listed in guidelines (no MCA aneurysm, typically low-grade bleeding, no ICH, minimal hydrocephalus risk)
- No vasospasm or delayed cerebral ischemia
- Essentially zero seizure risk in the literature
Clinical Bottom Line
Do not prescribe Keppra for perimesencephalic SAH. These patients lack all the high-risk features that would even remotely justify prophylactic antiseizure medication in the aneurysmal SAH population. The guidelines explicitly state that prophylaxis is "not beneficial" for low-risk aSAH 1—and perimesencephalic SAH is even lower risk than low-risk aSAH.
Common Pitfall to Avoid
Do not reflexively apply "SAH protocols" to perimesencephalic SAH. This benign entity requires minimal intervention: observation, blood pressure control, and reassurance. Unnecessary medications like levetiracetam expose patients to adverse effects (somnolence, behavioral changes, hematologic abnormalities 3) without any potential benefit.